Colectomy in Ulcerative Colitis: Trends in Southern Iran in a Decade

Sulmaz Ghahramani ¹ , Mahsa Paparisabet ², Mohammad Sayari ¹, Seyed Vahid Hosseini ³, Kamran Bagheri Lankarani ¹ *

Cited by CrossRef: 1

1- Pakdin M, Zarei L, Bagheri Lankarani K, Ghahramani S. The cost of illness analysis of inflammatory bowel disease. BMC Gastroenterol. 2023;23(1) [Crossref]

2- Niksalehi K, Oyarhossein A, Fariman S, Ahmadi A, Azadmehr B, Karimpour-Fard N, Vaziri L, Afzali M. Intravenous and subcutaneous vedolizumab for moderately to severely active ulcerative colitis in Iran: a model-based cost-effectiveness evaluation. Expert Review of Pharmacoeconomics & Outcomes Research. 2025;25(6):933 [Crossref]

3- El-Hussuna A, Hauer A, Karakan T, Pittet V, Yanai H, Devi J, Yamamoto-Furusho J, Sima A, Desalegn H, Sultan M, Sharma V, Shehab H, Mrabti L, Queiroz N, Jena A, Darma A, Davidson K, Avellaneda N, Elhadi M, Roslani A, Wickramasinghe D, Cajucom C, Sebastian S. ECCO consensus on management of inflammatory bowel disease in low- and middle-income countries. 2026;20(1) [Crossref]

Submit Your Paper Notification Instructions for Authors Aims and Scope Editorial policies Editorial Board AIM old site Archive

About Us

A Monthly Peer-Reviewed Medical Journal Published by the Academy of Medical Sciences of the I.R. Iran; Indexed in PubMed/MEDLINE, ISI Web of Science, EMBASE, SCOPUS, CINHAL, PASCAL, CSA, SID, ISSN: Print 1029-2977, Online 1735-3947.The impact factor of Archives of Iranian Medicine according to Journal Citation Reports® (JCR®) 2016 is 1.20.